Arch Therapeutics Inc
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and… Read more
Arch Therapeutics Inc (ARTH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: 0.073x
Based on the latest financial reports, Arch Therapeutics Inc (ARTH) has a cash flow conversion efficiency ratio of 0.073x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-911.64K) by net assets ($-12.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arch Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2023)
This chart illustrates how Arch Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Arch Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arch Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seya Industries Limited
NSE:SEYAIND
|
-0.011x |
|
Minera IRL Limited
PINK:MRLLF
|
-0.091x |
|
Woodlandor Holdings Bhd
KLSE:7025
|
-0.006x |
|
Sage Group PLC
LSE:SGE
|
0.393x |
|
Exceed World Inc
PINK:EXDW
|
-0.183x |
|
Tearlach Resources Ltd
V:TEA
|
-0.043x |
|
Insight Acquisition Corp. Class A Common Stock
NASDAQ:INAQ
|
0.091x |
|
Sino AG
XETRA:XTP
|
0.276x |
Annual Cash Flow Conversion Efficiency for Arch Therapeutics Inc (2013–2023)
The table below shows the annual cash flow conversion efficiency of Arch Therapeutics Inc from 2013 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-09-30 | $-7.51 Million | $-3.37 Million | 0.449x | -57.71% |
| 2022-09-30 | $-4.19 Million | $-4.46 Million | 1.063x | -81.71% |
| 2021-09-30 | $-1.03 Million | $-5.96 Million | 5.809x | +72.79% |
| 2020-09-30 | $-1.50 Million | $-5.04 Million | 3.362x | -48.48% |
| 2019-09-30 | $-807.30K | $-5.27 Million | 6.526x | +250.06% |
| 2018-09-30 | $1.36 Million | $-5.91 Million | -4.349x | -72.40% |
| 2017-09-30 | $2.23 Million | $-5.62 Million | -2.522x | -67.97% |
| 2016-09-30 | $3.16 Million | $-4.75 Million | -1.502x | +45.44% |
| 2015-09-30 | $1.54 Million | $-4.24 Million | -2.753x | -666.59% |
| 2014-09-30 | $-6.89 Million | $-3.35 Million | 0.486x | +106.33% |
| 2013-09-30 | $187.02K | $-1.43 Million | -7.671x | -- |